Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25832210 | 0.86 | APLNR (0.34) | APLNR | |
| SCHEMBL52124 | 0.86 | APLNR (0.34) | APLNR | |
| SCHEMBL31396189 | 0.83 | — | — | |
| SCHEMBL585726 | 0.83 | CYP1A2 (0.30) | — | |
| SCHEMBL7963544 | 0.82 | ESR2 (0.32) | — | |
| SCHEMBL16224739 | 0.79 | APLNR (0.31) | APLNR | |
| SCHEMBL11297009 | 0.78 | KDM4E (0.39) | — | |
| SCHEMBL1700392 | 0.77 | APLNR (0.30) | APLNR | |
| SCHEMBL28107803 | 0.77 | POLB (0.30) | — | |
| SCHEMBL4749397 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140113910-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-8197793-B2 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2012-06-12 | — | — | US | disclosed |
| US-8197793-B2 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2012-06-12 | — | — | US | disclosed |
| US-8197793-B2 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2012-06-12 | — | — | US | disclosed |
| EP-1601384-B1 | METHODS OF RADIOFLUORINATION OF BIOLOGICALLY ACTIVE VECTORS | GE HEALTHCARE AS (NO) | 2010-09-22 | — | — | EP | disclosed |
| EP-1601384-B1 | METHODS OF RADIOFLUORINATION OF BIOLOGICALLY ACTIVE VECTORS | GE HEALTHCARE AS (NO) | 2010-09-22 | — | — | EP | disclosed |
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2010-03-18 | — | — | US | disclosed |
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2010-03-18 | — | — | US | disclosed |
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2010-03-18 | — | — | US | disclosed |
| CN-100586485-C | Radiofluorination method of bioactive carrier | AMERSHAM HEALTH AS | 2010-02-03 | — | — | CN | disclosed |
| CN-1758925-A | Radiofluorination method of bioactive carrier | AMERSHAM HEALTH AS (NO) | 2006-04-12 | — | — | CN | disclosed |
| EP-1601384-A1 | METHODS OF RADIOFLUORINATION OF BIOLOGICALLY ACTIVE VECTORS | Amersham Health AS (NO) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004080492-A1 | METHODS OF RADIOFLUORINATION OF BIOLOGICALLY ACTIVE VECTORS | AMERSHAM HEALTH AS (NO) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113910-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | APLNR 1814/4885 |
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | DOHH, VGF, HNRNPH3 | APLNR 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.